Literature DB >> 25642763

Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with thymoglobulin GVHD prophylaxis.

A B M Lim1, J Storek2, A Beligaswatte3, M Collins4, M Tacey5, T Williamson2, K Mason6, E Li6, M A Chaudhry2, J A Russell2, A Daly2, J Szer1, I Lewis3, D Ritchie1.   

Abstract

Thymoglobulin (TG) given with conditioning for allogeneic haematopoietic SCT (alloHSCT) is effective in reducing the risk of acute and chronic GVHD (cGVHD). Whether conventional risk factors for GVHD apply to TG-conditioned alloHSCT is unknown. We retrospectively studied 356 adults from three centres who received TG 4.5 mg/kg prior to alloHSCT for haematologic malignancy. Donors were unrelated in 64%. At 3 years, OS was 61% (95% confidence interval (CI) 55-67%), cumulative incidence of relapse was 28% (95% CI 23-33%) and non-relapse mortality was 19% (14-24%). The cumulative incidences of grade 2-4, and grade 3-4 acute GVHD were 23% (95% CI 19-28%) and 10% (95% CI 6-13%), respectively. The cumulative incidence of cGVHD requiring systemic immunosuppression (cGVHD-IS) at 3 years was 32% (95% CI 27-37%). On multivariate analysis, counterintuitively, recipient age over 40 was associated with a significantly decreased risk of cGVHD-IS (P=0.001). We report for the first time a paradoxical association of older age with reduced cGVHD in TG recipients, and conclude that traditional risk factors for GVHD may behave differently in the context of pre-transplant TG.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25642763     DOI: 10.1038/bmt.2014.313

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  49 in total

1.  Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.

Authors:  Andrea Bacigalupo; Teresa Lamparelli; Giovanni Barisione; Paolo Bruzzi; Stefano Guidi; Paolo Emilio Alessandrino; Paolo di Bartolomeo; Rosi Oneto; Barbara Bruno; Nicoletta Sacchi; Maria Teresa van Lint; Alberto Bosi
Journal:  Biol Blood Marrow Transplant       Date:  2006-05       Impact factor: 5.742

2.  Using reduced intensity conditioning and HLA-identical sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose.

Authors:  M Remberger; J Mattsson; B-M Svahn; O Ringdén
Journal:  Bone Marrow Transplant       Date:  2008-08-11       Impact factor: 5.483

Review 3.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation.

Authors:  K M Sullivan; E Agura; C Anasetti; F Appelbaum; C Badger; S Bearman; K Erickson; M Flowers; J Hansen; T Loughran
Journal:  Semin Hematol       Date:  1991-07       Impact factor: 3.851

4.  Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.

Authors:  Scott D Rowley; Stuart L Goldberg; Andrew L Pecora; Jack S Hsu; Barbara Adler Brecher; Linda Butrin; Kelly Kobbe; Phyllis McKiernan; Robert Preti
Journal:  Biol Blood Marrow Transplant       Date:  2004-11       Impact factor: 5.742

5.  Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation.

Authors:  K Atkinson; M M Horowitz; R P Gale; D W van Bekkum; E Gluckman; R A Good; N Jacobsen; H J Kolb; A A Rimm; O Ringdén
Journal:  Blood       Date:  1990-06-15       Impact factor: 22.113

6.  Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation.

Authors:  Mats Remberger; Britt-Marie Svahn; Jonas Mattsson; Olle Ringdén
Journal:  Transplantation       Date:  2004-07-15       Impact factor: 4.939

7.  Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.

Authors:  Theresa Hahn; Philip L McCarthy; Mei-Jie Zhang; Dan Wang; Mukta Arora; Haydar Frangoul; Robert Peter Gale; Gregory A Hale; John Horan; Luis Isola; Richard T Maziarz; Jon J van Rood; Vikas Gupta; Joerg Halter; Vijay Reddy; Pierre Tiberghien; Mark Litzow; Claudio Anasetti; Stephen Pavletic; Olle Ringdén
Journal:  J Clin Oncol       Date:  2008-11-03       Impact factor: 44.544

8.  Peripheral-blood stem cells versus bone marrow from unrelated donors.

Authors:  Claudio Anasetti; Brent R Logan; Stephanie J Lee; Edmund K Waller; Daniel J Weisdorf; John R Wingard; Corey S Cutler; Peter Westervelt; Ann Woolfrey; Stephen Couban; Gerhard Ehninger; Laura Johnston; Richard T Maziarz; Michael A Pulsipher; David L Porter; Shin Mineishi; John M McCarty; Shakila P Khan; Paolo Anderlini; William I Bensinger; Susan F Leitman; Scott D Rowley; Christopher Bredeson; Shelly L Carter; Mary M Horowitz; Dennis L Confer
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

9.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Authors:  Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

10.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

View more
  2 in total

1.  Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Chien-Ting Chen; Chun-Yu Liu; Yuan-Bin Yu; Chia-Jen Liu; Liang-Tsai Hsiao; Jyh-Pyng Gau; Tzeon-Jye Chiou; Jing-Hwang Liu; Yao-Chung Liu
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

2.  Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.

Authors:  Rehan Mujeeb Faridi; Taylor J Kemp; Poonam Dharmani-Khan; Victor Lewis; Gaurav Tripathi; Raja Rajalingam; Andrew Daly; Noureddine Berka; Jan Storek; Faisal Masood Khan
Journal:  PLoS One       Date:  2016-06-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.